Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors

Anton G. Henssen(Memorial Sloan Kettering Cancer Center), Casie Reed(Memorial Sloan Kettering Cancer Center), Eileen Jiang(Memorial Sloan Kettering Cancer Center), Heathcliff Dorado García(Charité - Universitätsmedizin Berlin), Jennifer von Stebut(Charité - Universitätsmedizin Berlin), Ian C. MacArthur(Memorial Sloan Kettering Cancer Center), Patrick Hundsdoerfer(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Jun Hyun Kim(Memorial Sloan Kettering Cancer Center), Elisa de Stanchina(Memorial Sloan Kettering Cancer Center), Yasumichi Kuwahara(Kyoto Prefectural University of Medicine), Hajime Hosoi(Kyoto Prefectural University of Medicine), Neil J. Ganem(Boston University), Filemon S. Dela Cruz(Memorial Sloan Kettering Cancer Center), Andrew L. Kung(Memorial Sloan Kettering Cancer Center), Johannes H. Schulte(German Cancer Society), John H.J. Petrini(Memorial Sloan Kettering Cancer Center), Alex Kentsis(Memorial Sloan Kettering Cancer Center)
Science Translational Medicine
November 1, 2017
Cited by 63Open Access
Full Text

Abstract

-phase cells in the absence of immediate DNA replication stress. Accordingly, AZD6738 exhibited nanomolar potency against most neuroblastoma, medulloblastoma, Ewing sarcoma, and rhabdoid tumor cells tested while sparing nontransformed human and mouse embryonic fibroblasts in vitro. Finally, treatment with AZD6738 induced apoptosis and regression of human neuroblastoma and medulloblastoma tumors engrafted in immunodeficient mice in vivo. This effect was potentiated by combined treatment with cisplatin, including substantial antitumor activity against patient-derived primary neuroblastoma xenografts. These findings delineate a therapeutically actionable synthetic dependency induced in PGBD5-expressing solid tumors.


Related Papers

No related papers found

Powered by citation graph analysis